Table 1.
Criteria for guideline-concordant and -discordant groups to pharmacological recommendations in GOLD 2011 and 2017 guidelines
| Guidelines
|
Guideline concordant
|
Guideline discordant
|
|||
|---|---|---|---|---|---|
| GOLD 2011 | GOLD 2017 | GOLD 2011 and GOLD 2017 | |||
|
|
|
||||
| COPD classifications | First choice | Second choice | Recommended | Undertreatment | Overtreatment |
| Group A | SABA or SAMA, or SABA/SAMA | LABA or LAMA | SABA or SAMA, or SABA/SAMA, or LABA, or LAMA | Not any bronchodilator | LABA/LAMA, or ICS/LABA, or LAMA/ICS, or ICS/LABA/LAMA |
| Group B | LABA or LAMA | LABA/LAMA | LABA or LAMA or LABA/ LAMA | SABA, or SAMA, or SABA/SAMA | ICS/LABA, or LAMA/ICS, or ICS/LABA/LAMA |
| Group C | ICS/LABA or LAMA | LABA/LAMA | LAMA or LABA/LAMA or ICS/LABA | SABA, or SAMA, or SABA/SAMA, or LABA | ICS/LABA/LAMA, or LAMA/ICS |
| Group D | ICS/LABA or LAMA | ICS/LABA/LAMA, or LABA/LAMA, or LAMA/ICS | LAMA or LABA/LAMA or ICS/LABA, or ICS/LABA/ LAMA, or LAMA/ICS | SABA, or SAMA, or SABA/SAMA, or LABA | |
Abbreviations: SABA, short acting beta-agonist; SAMA, short-acting muscarinic-antagonist; LABA, long-acting beta-agonist; LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroid.